Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bora Pharmaceuticals CoTPE:6472 -1.60%83 3-Year EBITDA Growth Rate is 38.00% as of Jun. 2026, which is 48% below its 10-year median of 73.15. GuruFocus rates TPE:6472 with a GF Score™ of 83/100 and a GF Value™ of NT$727.63 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 809 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 83.81% on this metric.
During the past 12 months, Bora Pharmaceuticals Co's average EBITDA Per Share Growth Rate was -45.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 38.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 52.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 66.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bora Pharmaceuticals Co was 143.40% per year. The lowest was -2.20% per year. And the median was 73.15% per year.
Bora Pharmaceuticals Co (TPE:6472) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bora Pharmaceuticals Co 3-Year EBITDA Growth Rate Related Terms
TPE:6472 vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's 3-Year EBITDA Growth Rate falls into.
Bora Pharmaceuticals Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 38.00% mean?
Bora Pharmaceuticals Co (TPE:6472) has a 3-Year EBITDA Growth Rate of 38.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bora Pharmaceuticals Co and its competitors. This is 48% below median its historical median of 73.15. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #131 out of 809 companies in the Drug Manufacturers industry, placing it in the top 16.2%.
Is Bora Pharmaceuticals Co's 3-Year EBITDA Growth Rate too high?
Bora Pharmaceuticals Co's current 3-Year EBITDA Growth Rate of 38.00% is 48% below median its 10-year median of 73.15. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Bora Pharmaceuticals Co's value of 38.00% is 327% above this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #131 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bora Pharmaceuticals Co has a GF Score™ of 83/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #131 out of 809 companies for 3-Year EBITDA Growth Rate. This places Bora Pharmaceuticals Co in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Bora Pharmaceuticals Co's value of 38.00% is 327% above this benchmark. While the company's 10-year median is 73.15 vs. the industry median of 8.90, Bora Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current 3-Year EBITDA Growth Rate of 38.00% is 327% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current 3-Year EBITDA Growth Rate is 38.00%, which is 48% below median its own 10-year median of 73.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Possible Value Trap. The stock's GF Value™ is NT$727.63, compared to a current price of NT$399.00 — trading 45.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 38.00%, which is 48% below median its 10-year median of 73.15 and 327% above the Drug Manufacturers industry median of 8.90. Bora Pharmaceuticals Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current 3-Year EBITDA Growth Rate is 38.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$399.00 is trading 45.2% below its estimated GF Value™ of NT$727.63.
GuruFocus considers Bora Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for TPE:6472:
3-Year EBITDA Growth Rate: 38.00% (48% below median its 10-year median of 73.15)
GF Value™: NT$727.63 vs. price of NT$399.00 (45.2% below fair value)
Industry Position: 327% above the Drug Manufacturers median (#131 of 809)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
83GF Score
Get the complete analysis for TPE:6472
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
